Please ensure Javascript is enabled for purposes of website accessibility
Max Macaluso

Max Macaluso


Max is the Technology, Biopharma & Health Care Bureau Chief at Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.

Recent articles

3 Key Advances in HIV Prevention

New approaches to HIV prevention.

1 Thing You Always Wanted to Know About Drugs (but Were Afraid to Ask)

Two fascinating approaches pharmaceutical companies use to discover new drugs.

Hot Off the Press: Dynavax Tumbles 30%

What caused this biotech to crash this morning?

What's Ahead for Rigel Pharmaceuticals After This 18% Plunge?

AstraZeneca leaves its partnership with Rigel following lackluster results from Fostamatinib's late-stage trials.

Breakthrough Melanoma Data Drives Pharmas Higher

Why are Merck and Bristol-Myers Squibb up big today?

Clinical Trial Disappointment for This Pharmaceutical Giant

What does this mean for Merck going forward?

What Is the Largest Pharmaceutical Company on the Planet?

This question is more difficult to answer than you may think.

Ask a Fool: What Do You Think About AbbVie?

AbbVie has generated a lot of buzz in the pharmaceuticals space ever since it spun off from Abbott Labs. What do we think of it here at the Fool?

Ask a Fool: What's Behind Albany Molecular's Biggest Drop?

Albany Molecular beat on earnings and raised guidance. So why did the market react so poorly?

Does This Struggling Drugmaker Have an Ace Up Its Sleeve?

What drug candidate should Merck investors be watching?

What This Breakthrough Designation Means for Alexion Pharmaceuticals

This biotech's experimental hypophosphatasia drug was granted "breakthrough therapy designation" today.

Unclear Future for Merck's Insomnia Drug

The FDA advisory committee has discussed Suvorexant; now shareholders need to get ready for the agency's final decision this summer.

Regeneron and Sanofi: An Unstoppable Biotech Duo?

More positive clinical trial data released today.

What's Behind Medtronic's 5% Pop?

Fourth-quarter results impressed investors today.

Will the FDA Approve Merck's Insomnia Drug?

The advisory committee meeting is this Wednesday, but investors will have to wait until the summer to discover the Food and Drug Administration's decision.

AbbVie's New Crohn's Disease Drug Candidate

Galapagos and AbbVie's experimental Crohn's disease drug GLPG0634 is entering a phase 2 clinical study.

Is Keryx Biopharmaceuticals Burning Too Much Cash?

What is Keryx's burn rate, and how much cash does it have on hand?

AbbVie Investors, Watch This Management Change

What strategy will the company's new chief scientific officer pursue?

The New Generic-Drug Battle Front

One generic pharmaceutical company is determined to chance consumer habits.

3 Most Important Upcoming FDA Decisions of 2013

The Food and Drug Administration will decide on drugs developed by Merck, Antares Pharmaceuticals, and GlaxoSmithKline in the coming months.